With the support of Bluegreen, PlumeStars received the EU Seal of Excellence for a new oncology drug recognized by the EMA! PlumeStars is an innovative SME founded by a team of researchers specialized in drug delivery.
PlumeStars focuses on the development of orphan drugs, with expertise in inhaled antibiotics, implantable chemotherapeutics, and oral and nasal medications.
About the project
PlumeStars has obtained orphan drug designation and protocol assistance for three products: Amika PS, Hyalcis, and Taldo. The company holds a patented technology that enables the molecular deposition of fatty acids on drug microparticles, which can be applied to various pharmaceuticals. PlumeStars specifically focuses on developing antibiotics for the treatment of lung infections in patients with cystic fibrosis.